Whitepapers

As medical facilities become more equipped to handle different telemedicine platforms and procedures, more clinical trials are back up and running. This also means more electronic data is being generated than ever. This Ebook will explain how to reach patients and facilities, especially in this decentralized clinical trial format.

Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.

Patient selection can be a nuanced process in clinical trials, particularly those involving therapeutic areas with more complex or subjective inclusion/exclusion criteria. Determining patient eligibility may often depend on factors that require clinical expertise in such areas as disease progression, comorbidities, genetic mutations, and disease severity. Discover the role eligibility adjudication committees play in ensuring trial success.

EACs/CECs evaluate potential adverse events, participants’ safety, whether a patient meets complex eligibility criteria, and much more. Thus, the need to select the right EAC vendor is critical – selecting the wrong partner risks time, money, and success. With so many EAC vendors, it can be challenging to find the ideal partner. Fortunately, WCG has outlined the top five benefits of utilizing an independent EAC.

No clinical trial is successful without careful attention not only to how endpoints are crafted, but how they are reviewed and applied. This article will describe the use of Imaging Core Labs and Endpoint Adjudication Committees (EACs) to increase the quality and accuracy of clinical trial data. Additionally, it will clarify the differences between these critical endpoint review methods and other forms of safety review.

Is your eCOA provider built to deliver clinical trial success? Our eCOA checklist provides key questions to ask when evaluating potential vendors.

Learn how to develop and market products and interventions that actually meet individuals' needs by incorporating patient input exist throughout the trial lifecycle

Determining the most effective locations and formats to get your clinical trial in front of willing, eligible participants can seem like a daunting task.. What is the most efficient way to introduce more targeted recruitment approaches?

In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.

YPrime announces a new report unveiling the top challenges that clinical trial executives face when implementing eCOA, and what to look for when evaluating new solutions.

Digital biomarkers provide a pathway to the future where clinical trial sponsors can potentially benefit from reduced trial duration and sample size. Learn more about these benefits from a simulated study.

Digital biomarkers, smartphones, and wearables are transforming clinical trials by revolutionizing remote data collection and providing insights into treatment efficacy. Learn more about these exploratory endpoints and how they provide greater confidence in a clinical trial.

Explore the five key advantages that underscore the significance of digital measurements in the context of clinical trials

Learn how your team can use EHR-to-EDC technology to reduce data monitoring costs, speed up data cleaning timelines, and hit study milestones faster.

Looking for an EDC solution but overwhelmed by the process? This free guide highlights five steps to help you navigate the EDC vendor landscape and choose the right system for your study.

Inside this eBook, readers can expect to learn how to effectively navigate the various challenges associated with clinical trial data collection and reporting in the age of digitalization and at a time in which site staff are experiencing turnover and seeking more efficiency.

In this playbook, learn how a virtual site solution expands access to infectious disease clinical trials by allowing patients to enroll and participate from anywhere.

The rapid evolvement of precision oncology requires real-world data generated at a scale that unlocks insights that can not be provided from clinical trial evidence. Machine learning and large language models can be used to quickly identify information, supporting custom integrated real-world evidence solutions to make informed decisions.

Explore the pivotal role of Next-Generation Sequencing (NGS) panel customization in driving advancements in oncology research.

By employing effective use of the patient voice, companies can better boost patient engagement success.

This piece offers a practical assessment of leveraging various decentralized methodologies and technologies.

Delve into the impact of external stakeholder requirements in developing an integrated evidence generation strategy that maximizes product value.

Learn how strategic planning and patient-centric design of real-world studies drive value critical to stakeholder acceptance.